Nichole Tucker

: On the heels of positive findings from the phase 1/1b AURELIO-03, 1 patient with an advanced/refractory solid tumor has been dosed with SOT101 and pembrolizumab in the follow-up study, AURELIO-04.

Long-term follow-up in the COLUMBUS study shows continued survival improvement with encorafenib plus binimetinib and impressive disease control in patients with BRAF V600-mutant melanoma.

Treatment with ITI-3000 has begun in a first-in-human, phase 1 study of patients with Merkel cell carcinoma.

The developer of OP-1250 anticipates working closely with the FDA to expedite the development of the drug for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer.

The phase 2 LOTIS-9 study of loncastuximab tesirine-lpyl combined with rituximab has been initiated with the dosing of the first patient with previously untreated diffuse large B-cell lymphoma.

Following positive phase 1 study results for eltanexor monotherapy in patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndrome, the FDA has granted the drug fast track status.

The phase 3 OVAL clinical trial has been discontinued after the combination of ofranergene obadenovec and paclitaxel did not achieve the study’s primary end points of improvement in progression-free and overall survival.

Patients with unresected locally advanced head and neck squamous cell carcinoma did not show a significant improvement in event-free survival when treated with pembrolizumab and concurrent chemoradiation followed by pembrolizumab maintenance in the phase 3 KEYNOTE-412 study.

The addition of brentuximab vedotin to standard chemotherapy achieved a 41% reduction in the risk of death in patients with advanced-stage Hodgkin lymphoma in the ECHELON-1 study.

The phase 3 ZILO-301 study will evaluate the combination of zilovertamab and ibrutinib in patients with relapsed or refractory mantle cell lymphoma.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

In an interview with Targeted Oncology, Cristian Tomasetti, PhD, discussed the role of circulating tumor DNA in understanding the need for adjuvant chemotherapy in patients with stage II colon cancer. He explained how circulating tumor DNA can signal a patient’s risk of disease recurrence after surgery.

A highly anticipated presentation at the 2022 World Conference on Lung Cancer will be the first report of efficacy and safety from the phase 1b/2 CodeBreak 101 clinical trial and will provide updated results from the phase 2 CodeBreak 100 study.

Upcoming data from part C of the DisTinGuish study will further confirm the benefit and safety of DKN-01 in combination with tislelizumab in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal adenocarcinoma.

Visits to the phase 3 FLAMINGO-01 clinical trial sites have been initiated following the lift of a FDA clinical hold.

Based on findings from the TULIP study, [vic-] trastuzumab duocarmazine may be a new standard treatment option for patients with HER2-positive unresectable locally advanced metastatic breast cancer. a biologics license application has been accepted by the FDA.

In the interview with Targeted Oncology, Marcia S. Brose, MD, PhD, FASCO discussed treatment of TRK fusion-positive thyroid cancer based on the most recent data from 2022 ASCO Annual Meeting and ongoing studies.

The FDA has granted fast track designation to abelacimab for the treatment of thrombosis associated with cancer. The agent is being assessed in 2 phase 3 clinical trials.

In an interview with Targeted Oncology, Toni K. Choueiri, MD, discusses results from the KEYNOTE-564 efficacy analysis and what will come next for pembrolizumab treatment in renal cell carcinoma.

The recruitment of patients with melanoma has been completed in the phase 2 INITIUM clinical trial. Topline results from the study are expected to be reported in early 2023.

In the phase 3 TOPAZ-1 trial, the addition of durvalumab to standard-of-care chemotherapy achieved a statistically significant improvement in overall survival compared chemotherapy alone, meeting the study's primary end point.

The FDA has granted priority review to an approval application for mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma.

In the RATIONALE 306 clinical trial, the combination of tislelizumab and chemotherapy achieved a 34% reduction in the risk of death in patients with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma with either high or low PD-L1 expression.

In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.

Five-year data from the RESPONSE-2 study combined with prior RESPONSE study results show that there is an option for the roughly 40% of patients with polycythemia vera who become intolerant or resistant to hydroxyurea.

Findings from an analysis of the CAPTIVATE study imply that ibrutinib plus venetoclax may allow for effective subsequent retreatment with ibrutinib and/or venetoclax and enhance clinical benefit.

The FDA has granted breakthrough therapy designation to talquetamab for the treatment of previously-treated adult patients with relapsed or refractory multiple myeloma based on positive results from the phase 1/2 MonumenTAL-1 study.

In a phase 1 clinical trial, treatment with GFH009 showed early signal s of efficacy in patients with advanced relapsed or refractory lymphoma and acute myeloid leukemia.

In an interview with Targeted Oncology™, Karen L. Reckamp, MD, discussed that limited options for patients with advanced NSCLC who are resistant to immune checkpoint inhibitor therapy. Reckamp also discusses how Lung-MAP research might play a hand in bringing new therapies in the future.